Company / Financials
AYTU BIOPHARMA, INC Financials
FY2012-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$66.4M
FY2025 · +1.8% YoY
Net Income
-$13.6M
FY2025 · +14.4% YoY
Profit Margin
-20.4%
FY2025 · net income / revenue
ROE
-71.5%
FY2025 · return on equity
Total Assets
$124.2M
FY2025
Total Debt
$10.9M
0.57x debt/equity
Equity
$19.0M
FY2025
ROA
-10.9%
FY2025 · return on assets
Statement paths
Metric history
Revenue HistoryTotal revenue from operations$66.4M+1.8% YoYNet Income HistoryProfit after all expenses and taxes-$13.6M+14.4% YoYGross Profit HistoryRevenue minus cost of goods sold$45.8M-6.6% YoYCost of Revenue HistoryDirect costs of producing goods and services sold$20.6M+27.4% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$7.8M-392.0% YoYSG&A Expense HistorySelling, general, and administrative expenses$17.4M-12.9% YoYR&D Expense HistoryResearch and development spending$1.3M-52.1% YoYInterest Expense HistoryCost of borrowing and debt obligations-Income Tax HistoryTotal income tax expense$437.0K-79.6% YoYEPS (Basic) HistoryBasic earnings per share-$2.86+44.0% YoY